The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.
In this webinar, Dr. Lawrence Weiss from NeoGenomics will discuss his experience with the validation and implementation of testing for actionable PIK3CA mutations using the therascreen PIK3CA RGQ PCR Kit.
The webinar will provide an overview of an innovative approach to detecting PIK3CA mutations by testing either tissue or plasma samples and the benefits this brings to breast cancer care. An FDA-approved companion diagnostic test, the therascreen PIK3CA RGQ PCR Kit helps clinicians identify actionable PIK3CA mutations in breast cancer cases to inform patient treatment choices.
The webinar will focus on the following topics:
- Overview of HR+/HER2- breast cancer progression and resistance to endocrine therapy.
- The biology and activation of the PI3K pathway and its role in cancer.
- Validation and implementation of the therascreen PIK3CA RGQ PCR Kit for testing of both formalin-fixed, paraffin-embedded tissue and plasma samples.
- The provision of Day 1 availability of PIK3CA mutation companion diagnostic testing.
The therascreen PIK3CA RGQ PCR Kit is intended for in vitro diagnostic use. Products and product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.